Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (101-110 of 338) with videos related to

Pageof 34
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Exploiting regulatory T-cell populations for the immunotherapy of cancerHans J J van der Vliet, Henry B Koon, Michael B Atkins, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|July 11, 2009
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreasAram N Demirjian, Charles M Vollmer, David F McDermott, et al.
Clinical Genitourinary Cancer|May 5, 2021
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell CarcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
European Radiology|August 31, 2011
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experienceIvan Pedrosa, Khashayar Rafatzand, Philip Robson, et al.
Future Oncology (London, England)|August 1, 2023
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
Immunotherapy|March 12, 2019
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparisonMichael B Atkins, Ahmad Tarhini, Michael Rael, et al.
Radiology|July 21, 2007
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in miceAntoine Hakimé, Andrew Hines-Peralta, Himaja Peddi, et al.
Radiology|February 27, 2009
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findingsMaryellen R M Sun, Long Ngo, Elizabeth M Genega, et al.
Cancer|June 28, 2012
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanomaRajmohan Murali, Philip T Brown, Richard F Kefford, et al.
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Pageof 34

Showing results (101-110 of 338) with videos related to

Sort By:
Pageof 34
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Exploiting regulatory T-cell populations for the immunotherapy of cancerHans J J van der Vliet, Henry B Koon, Michael B Atkins, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|July 11, 2009
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreasAram N Demirjian, Charles M Vollmer, David F McDermott, et al.
Clinical Genitourinary Cancer|May 5, 2021
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell CarcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
European Radiology|August 31, 2011
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experienceIvan Pedrosa, Khashayar Rafatzand, Philip Robson, et al.
Future Oncology (London, England)|August 1, 2023
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
Immunotherapy|March 12, 2019
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparisonMichael B Atkins, Ahmad Tarhini, Michael Rael, et al.
Radiology|July 21, 2007
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in miceAntoine Hakimé, Andrew Hines-Peralta, Himaja Peddi, et al.
Radiology|February 27, 2009
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findingsMaryellen R M Sun, Long Ngo, Elizabeth M Genega, et al.
Cancer|June 28, 2012
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanomaRajmohan Murali, Philip T Brown, Richard F Kefford, et al.
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Pageof 34